• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Renal-adipose neural circuit underlies the weight-lowering effects of sodium-glucose co-transporter 2 inhibitors.

作者信息

Yasukawa Minoru, Shibata Shigeru

机构信息

Division of Nephrology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.

Advanced Comprehensive Research Organization, Teikyo University, Tokyo, Japan.

出版信息

Hypertens Res. 2025 Aug 18. doi: 10.1038/s41440-025-02341-6.

DOI:10.1038/s41440-025-02341-6
PMID:40826232
Abstract
摘要

相似文献

1
Renal-adipose neural circuit underlies the weight-lowering effects of sodium-glucose co-transporter 2 inhibitors.肾-脂肪神经回路是钠-葡萄糖协同转运蛋白2抑制剂降体重作用的基础。
Hypertens Res. 2025 Aug 18. doi: 10.1038/s41440-025-02341-6.
2
Sodium-glucose co-transporter 2 inhibitor-induced increase in adenosine promotes lipolysis and weight reduction by activating reno-adipose autonomic neurocircuitry.钠-葡萄糖协同转运蛋白2抑制剂诱导的腺苷增加通过激活肾-脂肪自主神经回路促进脂肪分解和体重减轻。
Hypertens Res. 2025 Jul 23. doi: 10.1038/s41440-025-02287-9.
3
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.用于治疗糖尿病和慢性肾脏病患者的胰岛素及降糖药物。
Cochrane Database Syst Rev. 2018 Sep 24;9(9):CD011798. doi: 10.1002/14651858.CD011798.pub2.
4
Sodium-Glucose Cotransporter 2 Inhibitors and Changes in Epicardial Adipose Tissue: A Systematic Literature Review And Meta-Analysis.钠-葡萄糖协同转运蛋白2抑制剂与心外膜脂肪组织的变化：一项系统文献综述和荟萃分析
Curr Vasc Pharmacol. 2025;23(3):204-212. doi: 10.2174/0115701611330060241204062248.
5
Use of sodium-glucose co-transporter 2 inhibitors in solid organ transplant recipients with pre-existing type 2 or post-transplantation diabetes mellitus: A systematic review.钠-葡萄糖协同转运蛋白2抑制剂在患有2型糖尿病或移植后糖尿病的实体器官移植受者中的应用：一项系统评价。
Transplant Rev (Orlando). 2023 Jan;37(1):100729. doi: 10.1016/j.trre.2022.100729. Epub 2022 Nov 4.
6
Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂治疗 2 型糖尿病的药效学、疗效和安全性。
Drugs. 2015 Jan;75(1):33-59. doi: 10.1007/s40265-014-0337-y.
7
Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂用于慢性肾脏病和糖尿病患者。
Cochrane Database Syst Rev. 2024 May 21;5(5):CD015588. doi: 10.1002/14651858.CD015588.pub2.
8
Effects of sodium-glucose co-transporter-2 inhibitors on kidney, cardiovascular, and safety outcomes in patients with advanced chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.钠-葡萄糖协同转运蛋白 2 抑制剂对晚期慢性肾脏病患者肾脏、心血管和安全性结局的影响：一项随机对照试验的系统评价和荟萃分析。
Acta Diabetol. 2023 Mar;60(3):325-335. doi: 10.1007/s00592-022-01989-7. Epub 2022 Nov 1.
9
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.SGLT2 抑制剂对肾脏的保护作用：在急性和慢性肾脏病中的作用。
Curr Diab Rep. 2022 Jan;22(1):39-52. doi: 10.1007/s11892-021-01442-z. Epub 2022 Feb 3.
10
Effects of sodium-glucose co-transporter-2 inhibitors on anthropometric indices and metabolic markers in overweight/obese individuals without diabetes: a systematic review and meta-analysis.钠-葡萄糖协同转运蛋白2抑制剂对无糖尿病超重/肥胖个体人体测量指标和代谢标志物的影响：一项系统评价和荟萃分析
Curr Med Res Opin. 2022 Nov;38(11):1853-1863. doi: 10.1080/03007995.2022.2115775. Epub 2022 Aug 30.

本文引用的文献

1
Dapagliflozin in Patients with Chronic Kidney Disease.达格列净治疗慢性肾脏病患者。
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
2
Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity.钠-葡萄糖协同转运蛋白 2 抑制剂在肥胖治疗中的新作用。
Drugs. 2019 Feb;79(3):219-230. doi: 10.1007/s40265-019-1057-0.
3
Twenty-Four-Hour Blood Pressure-Lowering Effect of a Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Diabetes and Uncontrolled Nocturnal Hypertension: Results From the Randomized, Placebo-Controlled SACRA Study.
钠-葡萄糖协同转运蛋白2抑制剂对糖尿病合并未控制夜间高血压患者的24小时降压效果：随机、安慰剂对照SACRA研究结果
Circulation. 2019 Apr 30;139(18):2089-2097. doi: 10.1161/CIRCULATIONAHA.118.037076. Epub 2018 Nov 29.
4
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.卡格列净与 2 型糖尿病的心血管和肾脏事件。
N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.
5
Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病患者血压的影响：对43项随机对照试验（涉及22528例患者）的系统评价和荟萃分析
J Am Heart Assoc. 2017 May 25;6(6):e004007. doi: 10.1161/JAHA.116.004007.
6
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.恩格列净：在 2 型糖尿病中的心血管结局和死亡率。
N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.